Abstract
Abundant epidemiological experimental and clinical data support a primary atherogenic role for plasma low density lipoproteins (LDL) (1). The mechanism by which LDL are mostly cleared from the blood circulation is the LDL receptor pathway which is normally regulated by a feedbak mechanism thus preventing the accumulation of cholesterol esters in the cells (2). This pathway is altered in familial hypercholesterolemia (FH). The homozygous form of FH, in which LDL receptors are severely deficient (10%), occurs in only one subject out of every million. Heterozygotes, with a consistent reduction of receptors (50%), represent one out of every 500 persons (3). Among patients with myocardial infarctions under age 60 5% have a genetic defect of the LDL specific receptors (3). It happens therefore that coronary atherosclerosis, as well the others pictures of the clinical atherosclerosis, is mostly present in people having a normal receptorial system. The accumulation of cholesteryl esters in the foam cells, the peculiar trait of the atherosclerotic plaque, has to happen therefore through other pathways. Foam cells derive from two cellular sources: the arterial smooth muscle cells (SMC) and the monocytes-derived macrophages (MM) (4). The latter cells type, unlike many other cells, take up only a little amount of LDL by the receptor-mediated endocytosis mechanism, but have a distinct receptorial system that binds and degrades the more negatively charged LDL (5, 6).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
W. B. Kannel, W. P. Castelli, T. Gordon, and P. M. McNamara, Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann. Intern. Med. 74: 1 (1971).
J. L. Goldstein, and M. S. Brown, Low density lipoprotein pathway and its relation to atherosclerosis. Annu. Rev. Biochem. 46: 897 (1977)
J. L. Goldstein, and M. S. Brown, Familial hypercholesterolemia, in: “The metabolic basis of inherited disease. V”, J. B. Stanbury, J. B. Wyngaarden, D. S. Fredrickson, J. L. Goldstein, M. S. Brown, eds., McGraw Hill Co, 672 (1983).
R. Ross, Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components. Arteriosclerosis 1: 293 (1981).
J. L. Goldstein, Y. K. Ho, S. K. Basu, and M. S. Brown, Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoproteins, producing massive cholesterol ester deposition, Proc. Natl. Acad. Sci. USA 76: 333 (1979).
O. Stein, and Y. Stein, Bovine aortic endothelial cells display macrophage-like properties towards acetylated 125I-labelled low density lipoproteins, Biochim. Biophys. Acta 620: 631 (1980)
J. L. Goldstein, and M. S. Brown, Insights into the pathogenesis of atherosclerosis derived from studies of familial hypercholesterolemia, in: “Metabolic risk factors in ischemic cardiovascular disease ”, L. A. Carlson, and B. Pernow, eds., Raven Press, New York, 17 (1982).
A. M. Fogelman, I. Shechter, J. Seager, M. Hokom, J. S. Childs and P. A. Edwards, Malondialdehyde alteration of low density lipoproteins leads to cholesterol ester accumulation in human monocyte-derived macrophages, Proc. Nat. Acad. Sci. USA, 77: 2214 (1980)
T. Henriksen, E. Mahoney, and D. Steinberg, Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoprotein, Proc. Nat. Acad. Sci. USA 78: 6499 (1981).
J. R. Hessler, D. W. Morel, J. L. Lewis, and G. M. Chisolm, Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 3: 213 (1983).
T. Henriksen, S. A. Evensen, and B. Carlander, Injury to human endothelial cells in culture induced by low density lipoproteins. Scand. J. Clin. Lab. Invest., 39: 361 (1979).
J. Schuh, A. Novogzodisky, and R. H. Haschemeyer, Inhibition of lymphocyte mitogenesis by autoxidized low density lipoproteins. Biochem. Biophys. Res. Comm., 84: 763 (1978)
U. P. Steinbrecher, S. Parthasazathy, D. S. Leake, J. L. Witzum, and D. Steinberg, Modification of low density lipoproteins by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA 81: 3883 (1984)
I. Nishigaki, H. Hagihara, H. Tusunekawa, M. Maseki, and K. Yagi, Lipid peroxide levels of serum lipoprotein fractions of diabetic pateints. Biochem. Med., 25: 373 (1981)
Y. Goto, Lipid peroxides as a cause of vascular diseases, in: “Lipid peroxides in biology and medicine”, K. Yagi, ed., Academic Press Inc., New York 295 (1982)
G. Bittolo Bon, G. Cazzolato, and P. Avogaro, Changes of apolipoprotein B molecular weight and immunoreactivity in malondialdehyde-modified low density lipoproteins, Artery 12: 74 (1983).
G. Bittolo Bon, G. Cazzolato, S. Zago, and P. Avogaro, Effects of pantethine on in-vitro peroxidation of low density lipoproteins. Atherosclerosis 57: 99 (1985).
H. F. Hoff, LDL with altered surface charge: a new risk factor in atherogenesis? Artery 6: 178 (1979).
W. A. Pryor, L. Castle, Chemical methods for detection of lipid hydroperoxides, in: “Methods in Enzymology 105: oxigen radicals in biological systems”, L. Packer, ed., Academic Press 293 (1984).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
Avogaro, P., Bon, G.B., Cazzolato, G. (1987). Meaning of a Modified LDL in Humans. In: Malmendier, C.L., Alaupovic, P. (eds) Lipoproteins and Atherosclerosis. Advances in Experimental Medicine and Biology, vol 210. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1268-0_30
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1268-0_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-1270-3
Online ISBN: 978-1-4684-1268-0
eBook Packages: Springer Book Archive